Table 4.
Safety evaluation including brain natriuretic peptide (BNP) and haemodynamic data at baseline and 12 weeks
| Non-CR group (n=24) | CR group (n=17) | Between-group p value |
|||||
|---|---|---|---|---|---|---|---|
| Baseline | 12 weeks | Within-group p value |
Baseline | 12 weeks | Within-group p value |
||
| BNP level (pg/mL) | 28 (16–39) | 22 (16–48) | 0.96# | 22 (15–41) | 35 (20–45) | 0.52# | 0.76## |
| Haemodynamic data | |||||||
| Mean PAP (mm Hg) | 24.9±4.9 | 25.2±5.3 | 0.73 | 24.5±6.4 | 24.8±4.1 | 0.77 | 0.91 |
| Mean RAP (mm Hg) | 1.5 (0.0–3.0) | 3.0 (2.0–3.0) | 0.33# | 1.0 (0.5–2.0) | 2.0 (1.0–3.5) | 0.01# | 0.23## |
| Cardiac index (L/min/m2) | 2.54±0.53 | 2.52±0.54 | 0.86 | 2.62±0.50 | 2.48±0.55 | 0.19 | 0.52 |
| TPR (dyne.s/cm5) | 544±189 | 561±194 | 0.38 | 507±178 | 545±154 | 0.08 | 0.61 |
Results are expressed as mean±SD or median (25% and 75% centile). Within-group p values from #Wilcoxon signed-rank tests or otherwise paired t tests. Between-group p values from ##the Mann–Whitney U test comparing the changes from baseline or otherwise ANCOVA.
CR, cardiac rehabilitation; PAP, pulmonary arterial pressure; RAP, right atrial pressure; TPR, total pulmonary resistance.